clinical trial · NCT03720626
Managed Access Programs for SEG101, Crizanlizumab
Sickle Cell Diseasecrizanlizumab
brief summary
The purpose of this registration is to list Managed Access Programs (MAPs) related to SEG101, Crizanlizumab
started
—
primary completion
—
completion
—
last updated
Apr 14, 2026
detailed description
CSEG101A2001M - Available - Managed Access Program (MAP) Cohort Treatment Plan CSEG101A2001M to provide access to Crizanlizumab for sickle cell disease patients with history of vaso-occlusive crisis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol